Hi Benny,
Brent did a proactiv investors interview last week following the 18th annual bioshares summit. Video attached below
I can see your point on 4 and- and is was part of key takeaways I have taken from this video
1/ 3 x faster than manual review on petrie dish analysis and just as effective
2/ Astra Zeneca was referred to as a "cornerstone customer"
3/18 months ago strategy was pivoted from infectious diseases to pharma manufacturing which is a $2.8bn addressable market
4/ The "big one" coming is Astra Zeneca finalizing validating the tech then they will look at rolling out to their biggest manufacturing sites globally -looking at sept/oct mark
5/ New bit of information we have shared they have started an evaluation with two more top 10 global pharma companies
Ann: APAS PharmaQC Commercially Ready - Performance Finalised, page-81
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.001(3.23%) |
Mkt cap ! $27.98M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.6¢ | $31.62K | 1.976M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1847724 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 1063750 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| LBT (ASX) Chart |